Fig. 1

Progression-free survival (PFS) curves of epidermal growth factor receptor (EGFR)-mutated patients treated with tyrosine kinase inhibitors (TKIs). a PFS curves of patients with the EGFR exon 19 deletion (19 del) and exon 21 L858R point mutation (L858R mutation) who received first-line TKI therapy (14.4 vs. 11.4 months, P = 0.034); b PFS curves of patients with the EGFR 19 del and L858R mutation who received second-line or greater TKI therapy (11.7 vs. 11.2 months, P = 0.371)